Abstract: A composition including an immunoconjugate and a chemotherapeutic agent. The immunoconjugate includes 1) one or more interleukins, and 2) an Fc domain consisting of a first Fc subunit and a second Fc subunit. The first Fc subunit associates with the second Fc subunit to form a dimer. The one or more interleukins are fused to the Fc domain and the chemotherapeutic agent includes a fluorouracil and/or an oxaliplatin.

Abstract: An isolated antigen-binding protein, having one or more of the following properties: 1) capable of binding to human and monkey-derived GITR proteins at a KD value of 7×10?12 or below, wherein the KD value is measured by BLI method; 2) capable of stimulating immune cell proliferation; 3) capable of stimulating immune cells to secrete IFN-?, wherein the secretion is measured in T cell viability assay; 4) capable of inhibiting tumor growth and/or tumor cell proliferation; 5) capable of activating GITR signaling pathway; 6) capable of inhibiting the binding of GITR to GITRL.

Abstract: Proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.